Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
10 studies found for:    GLPG0634 | Phase 2, 3
Show Display Options
Rank Status Study
1 Completed Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease
Condition: Crohn's Disease
Interventions: Drug: GLPG0634;   Drug: Placebo
2 Enrolling by invitation Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Patients
Condition: Rheumatoid Arthritis
Intervention: Drug: GLPG0634
3 Completed Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Patients (DARWIN2)
Condition: Rheumatoid Arthritis
Interventions: Drug: GLPG0634;   Drug: Placebo
4 Completed Dose-ranging Study With GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients
Condition: Rheumatoid Arthritis
Interventions: Drug: GLPG0634;   Drug: Placebo
5 Completed Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Patients (DARWIN1)
Condition: Rheumatoid Arthritis
Interventions: Drug: GLPG0634;   Drug: Placebo
6 Completed Safety and Preliminary Efficacy of GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients
Condition: Rheumatoid Arthritis
Intervention: Drug: GLPG0634
7 Not yet recruiting Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease
Condition: Crohn's Disease
Interventions: Drug: Filgotinib;   Drug: Placebo
8 Recruiting Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease
Condition: Crohn's Disease
Interventions: Drug: Filgotinib;   Drug: Placebo to match filgotinib
9 Not yet recruiting Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis
Condition: Ulcerative Colitis
Interventions: Drug: Filgotinib;   Drug: Placebo
10 Recruiting Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis
Condition: Ulcerative Colitis
Interventions: Drug: Filgotinib;   Drug: Placebo to match filgotinib

Study has passed its completion date and status has not been verified in more than two years.